| Viatris is a global healthcare company. Co.'s portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas. Co. has four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Key products sold by the Developed Markets segment include Lyrica®, Lipitor®, Creon®, Influvac®, Wixela Inhub, and the EpiPen® Auto-Injector. Key products within the Greater China segment include Lipitor®, Norvasc®, and Viagra®. Key products within the JANZ segment include AMITIZA®, Lipacreon®, Lyrica®, Norvasc®, and Effexor®. Among Co.'s products sold in the Emerging Markets segment are Lipitor®, Lyrica®, Norvasc®, Celebrex®, and anti-retrovirals. |
When researching a stock like Viatris, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from VTRS Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for VTRS stock — the real life supply and demand for the stock over time — and examines that data in different ways.